Myelodysplastic syndrome (MDS) is a blood disorder characterized by the ineffective production of blood cells in the bone marrow, leading to a deficiency of red blood cells, white blood cells, and platelets. The exact cause is often unknown, but factors such as exposure to chemicals, previous chemotherapy or radiation therapy, and genetic predispositions increase the risk. Symptoms of MDS can vary depending on the disease’s type and severity and include fatigue, weakness, shortness of breath, frequent infections, easy bleeding or bleeding, and pale skin. Diagnosis typically involves a comprehensive evaluation by a hematologist, which includes a complete blood count, bone marrow biopsy and aspiration, and cytogenetic analysis. These findings determine the specific type and risk level of MDS, guiding the treatment approach.
Myelodysplastic syndrome (MDS) treatment is individualized and depends on factors like the patient’s subtype, overall health, age, and risk stratification. Lower-risk MDS patients may receive supportive care like blood transfusions and growth factors. For higher-risk MDS patients, the goal often shifts towards disease modification and potential cure. Hematopoietic stem cell transplant (HSCT), also known as bone marrow transplant, is a more aggressive treatment option. Haplo-identical bone marrow transplant (haplo-BMT) is a viable option for those without a fully matched donor. This type of transplant uses a half-matched donor, typically a parent or sibling, and involves chemotherapy and/or radiation to eradicate the diseased bone marrow. Advancements in conditioning regimens and post-transplant care have made haplo-BMT a viable and often life-saving option for MDS patients.
Mrs. B. K. Aruna from Hyderabad successfully underwent Haplo-Identical Bone Marrow Transplant for Myelodysplastic Syndrome (MDS) at Yashoda Hospitals, Hyderabad, under the supervision of Dr. Ganesh Jaishetwar, onsultant Hematologist, Hemato-Oncologist & Bone Marrow Transplant Physician.